Abstract
The aim of this study is to assess the morbidity and mortality related to cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colo-rectal carcinomatosis. A retrospective multi-institutional study from seven Italian Centers was performed. One hundred and seventy-two patients, submitted to cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) to treat carcinomatosis of colorectal origin, were recorded. Postoperative morbidity was evaluated in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Post-operative mortality was evaluated as patients’ death within 60 days from surgical procedures. Predictors of morbidity were evaluated with univariate and multivariate analyses. Post-operative morbidity occurred in 83 patients (48.3%): grades 1–2 in 29 cases (16.9%), and grades 3–4 in 54 (31.4%). Mortality occurred in four cases (2.3%). Number of anastomoses (OR 1.45; 95% CI 1.05–2.00; p = 0.024), number of blood transfusions (OR 1.31; 95% CI 1.11–1.54; p = 0.001) and chemotherapy regimen [Oxaliplatin (OX): OR 2.87; 95% CI 1.22–6.75; p = 0.015] remained, in multivariate analysis, in a statistically significant correlation with overall morbidity. The only variable that was proven to have statistically significant correlation with 3–4 morbidity was the number of blood transfusions (OR 1.25; 95% CI 1.07–1.46; p = 0.005). Morbidity and mortality do not preclude the use of CRS plus HIPEC in the treatment of peritoneal carcinomatosis of colorectal origin.
Similar content being viewed by others
References
Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JW, de Hingh IH (2011) Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 128:2717–2725. https://doi.org/10.1002/ijc.25596
Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A (2012) Incidence, prevalence and risk factors for peri-toneal carcinomatosis from colorectal cancer. Br J Surg 99:699–705. https://doi.org/10.1002/bjs.8679
Jayne DG, Fook S, Loi C et al (2002) Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89:1545–1550. https://doi.org/10.1002/bjs.8679
Dawson LE, Russell AH, Tong D, Wisbeck WM (1983) Adenocarcinoma of the sigmoid colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. J Surg Oncol 22:95–99
Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC (1989) Peritoneal carcinomatosis in nongynecologic malignancy. a prospective study of prognostic factors. Cancer 63:364–367
Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, François Y, Vignal J, Gilly FN (2000) Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 88:358–363
Glehen O, Osinsky D, Beaujard AC, Gilly FN (2003) Natural history of peritoneal carcinomatosis from nongynecologic malignancies. Surg Oncol Clin N Am 12:729–739
Berthelot C, Morel O, Girault S, Verrièle V, Poirier AL, Moroch J, Boucher Y, Le Jeune JJ, Lorimier G (2011) Use of FDG-PET/CT for peritoneal carcinomatosis before hyperthermic intra- peritoneal chemotherapy. Nucl Med Commun 32:23–29. https://doi.org/10.1097/mnm.0b013e328340e730
Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP (2006) Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 243:212–222
Yan TD, Morris DL, Shigeki K, Dario B, Marcello D (2008) Preoperative investigations in the management of peritoneal surface malignancy with cytoreductive surgery and peri-operative intraperitoneal chemotherapy: expert consensus statement. J Surg Oncol 98:224–227. https://doi.org/10.1002/jso.21069
Macrì A, Saladino E, Bartolo V, Adamo V, Altavilla G, Mondello E, Condemi G, Sinardi A, Famulari C (2010) Peritoneal carcinomatosis of colorectal origin. World J Gastrointest Oncol 2:98–101. https://doi.org/10.4251/wjgo.v2.i2.98
Sugarbaker PH (1998) Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 14:254–261
Sugarbaker PH (1999) Management of peritoneal surface malignancy: the surgeon’s role. Langenbecks Arch Surg 384:576–587
Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737–3743
Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, Gutman M, Tentes AA, Lorimier G, Bernard JL, Bereder JM, Porcheron J, Gomez-Portilla A, Shen P, Deraco M, Rat P (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi- institutional study. J Clin Oncol 22:3284–3292
Macrì A, Maugeri I, Trimarchi G, Caminiti R, Saffioti MC, Incardona S, Sinardi A, Irato S, Altavilla G, Adamo V, Versaci A, Famulari C (2009) Evaluation of quality of life of patients submitted to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis of gastrointestinal and ovarian origin and identification of factors influencing outcome. Vivo 23(1):147–150
Cotte E, Passot G, Gilly FN, Glehen O (2010) Selection of patients and staging of peritoneal surface malignancies. World J Gastrointest Oncol 2:31–35. https://doi.org/10.4251/wjgo.v2.i1.31
Macrì A, Saladino E, Trimarchi G, Bartolo V, Rossitto M, Cannaò A, Rizzo A, Famulari C (2011) Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in elderly patients. Vivo 25(4):687–690
Arjona-Sánchez A, Medina-Fernández FJ, Muñoz-Casares FC, Casado-Adam A, Sánchez-Hidalgo JM, Rufián-Peña S (2014) Peritoneal metastases of colorectal origin treated by cytoreduction and HIPEC: an overview. World J Gastrointest Oncol 6:407–412. https://doi.org/10.4251/wjgo.v6.i10.407
Macrì A, Arcoraci V, Belgrano V, Caldana M, Cioppa T, Costantini B, Cucinotta E, De Cian F, De Iaco P, De Manzoni G, Di Giorgio A, Fleres F, Muffatti F, Orsenigo E, Pinna AD, Roviello F, Sammartino P, Scambia G, Saladino E (2014) Short-term outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: preliminary analysis of a multicentre study. Anticancer Res 34:5689–5693
Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Available from https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed 28 May 2009
Jaquet P, Sugarbaker (1996) Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 15:49–58
Marz L, Piso P (2015) Treatment of peritoneal metastases from colorectal cancer. Gastroenterol Rep 3:298–302. https://doi.org/10.1093/gastro/gov044
Chua TC, Yan TD, Saxena A, Morris DL (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? a systematic review of morbidity and mortality. Ann Surg 249:900–907. https://doi.org/10.1097/sla.0b013e3181a45d86
Stewart JH IV, Shen P, Levine EA (2008) Intraperitoneal hyperthermi chemotherapy: an evolving paradigm for the treatment of peritoneal surface malignancies. Expert Rev Anticancer Ther 8:1809–1818. https://doi.org/10.1586/14737140.8.11.1809
Saladino E, Fleres F, Mazzeo C, Pruiti V, Scollica M, Rossitto M, Cucinotta E, Macrì A (2014) The role of prophylactic hyperthermic intraperitoneal chemotherapy in the management of serosal involved gastric cancer. Anticancer Res 34(4):2019–2022
Kusamura S, Younan R, Costanzo Baratti D, Favaro PM, Gavazzi C, Deraco M (2006) Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer 106:1144–1153
Glehen O, Osinsky D, Cotte E, Kwiatkowski F, Freyer G, Isaac S, Trillet-Lenoir V, Sayag-Beaujard AC, François Y, Vignal J, Gilly FN (2003) Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of periotneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 10:863–869
Hansson J, Graf W, Pahlman L, Nygren P, Mahteme H (2009) Postoperative adverse events and long-term survival after cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol 35:202–208. https://doi.org/10.1016/j.ejso.2008.04.002
Casado-Adam A, Alderman R, Stuart OA, Chang D, Sugarbaker PH (2011) Gastrointestinal complications in 147 consecutive patients with peritoneal surface malignancy treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy. Int J Surg Oncol 2011:468698. https://doi.org/10.1155/2011/468698
Mizumoto A, Canbay E, Hirano M, Takao N, Matsuda T, Ichinose M, Yonemura Y (2012) Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a single institution in Japan. Gastroenterol Res Pract 2012:836425. https://doi.org/10.1155/2012/836425
Di Giorgio A, De Iaco P, De Simone M, Garofalo A, Scambia G, Pinna AD, Verdecchia GM, Ansaloni L, Macrì A, Cappellini P, Ceriani V, Giorda G, Biacchi D, Vaira M, Valle M, Sammartino P (2017) Cytoreduction (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: retrospective Italian multicenter observational study of 511 cases. Ann Surg Oncol 24(4):914–922. https://doi.org/10.1245/s10434-016-5686-1
Smeenk RM, Verwaal VJ, Zoetmulder FA (2007) Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg 94:1408–1414
Kusamura S, Baratti D, Deraco M (2012) Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal sur- face malignancies. Ann Surg 255:348–356. https://doi.org/10.1097/sla.0b013e3182436c28
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Research involving human participants
The manuscript reports an observational retrospective study, so, on the basis of the resolution of the Authority for the Protection of Personal Data (Gazzetta Ufficiale N° 72 - March 26, 2012 – http://www.garanteprivacy.it/garante/doc.jsp?ID=1878276).
Informed consent
For this type of article, informed consent is not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Italian Peritoneal Surface Malignancies Oncoteam: Antonio Macrì, Franco De Cian, Giovanni De Manzoni, Michele De Simone, Elena Orsenigo, Manuela Robella, Franco Roviello, Paolo Sammartino, Marco Vaira.
Rights and permissions
About this article
Cite this article
Macrì, A., Arcoraci, V., Belgrano, V. et al. Short-term outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy used as treatment of colo-rectal carcinomatosis: a multicentric study. Updates Surg 72, 163–170 (2020). https://doi.org/10.1007/s13304-019-00691-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13304-019-00691-8